The Clinicians’ Guide to Managing Immune-Related Adverse Events: An Interactive Algorithm Tool

Download All
This multifaceted program, which includes a text module and an interactive algorithm tool, equips clinicians with guideline-driven recommendations to inform their evaluation and management of immune-related adverse events resulting from checkpoint inhibition.
Jeffrey S. Weber, MD, PhD
Program Director
Michael Postow, MD
Osama E. Rahma, MD
Jeffrey S. Weber, MD, PhD

ClinicalThought

Using 2 real-world clinical scenarios, this commentary focuses on practical strategies to manage pulmonary and endocrine adverse events associated with checkpoint inhibition in melanoma.

Jeffrey S. Weber, MD, PhD Released: September 26, 2016

This commentary describes 2 cases from my clinic and our experience managing hepatic, neurologic, and hematologic adverse events in patients treated for melanoma with immune checkpoint inhibitors.

Michael Postow, MD Released: October 27, 2016

How do preexisting autoimmune conditions such as ulcerative colitis and rheumatoid arthritis affect management of melanoma with checkpoint inhibitors?

Osama E. Rahma, MD Released: February 8, 2017

Module

In this CME-certified educational module, CCO’s expert faculty members highlight case-based examples to discuss the management of adverse events during checkpoint inhibitor therapy.

Jeffrey S. Weber, MD, PhD
Program Director
Michael Postow, MD Osama E. Rahma, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 3, 2017 Expired: No longer available for credit
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue